All In Biotech

NDA 212155 · Ge Healthcare

Cerianna

Fluoroestradiol F-18 · Intravenous · Radioactive Diagnostic Agent

Novel

Last checked: Nov 20, 2026Latest source record: May 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 20, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

11

0 Phase 3, 2 recruiting

FAERS reports

22

3 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2026.

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. ( 1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). ( 1 , 5.1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).

Mechanism: Fluoroestradiol F 18 binds ER. The following binding affinity: Kd = 0.13 ± 0.02 nM, Bmax = 1901 ± 89 fmol/mg, and IC 50 = 0.085 nM, was determined in an ER-positive human breast cancer cell line (MCF-7).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • CERIANNA · FLUOROESTRADIOL F-18 50ML (4-100mCi/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluoroestradiol F-18" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event14
  • false negative investigation result5
  • drug ineffective4
  • inappropriate release of product for distribution2
  • product with quality issue administered2
  • radioisotope scan abnormal2
  • seizure2
  • burning sensation1
  • false negative radioisotope investigation result1
  • false positive investigation result1
  • false positive radioisotope investigation result1
  • gait disturbance1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20233
20245
20255
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Ge Healthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.